ACRV - Company ID 0001781174
The table below shows Acrivon Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $41.42M | $34.06M | $35.41M | $41.90M | $39.15M | $43.41M |
| Short-term investments | $48.54M | $63.67M | $93.85M | $95.53M | $110.48M | $144.04M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $91.49M |
| $99.22M |
| $130.36M |
| $138.41M |
| $151.33M |
| $188.98M |
| Property, plant & equipment | $4.25M | $4.65M | $5.19M | $5.07M | $4.68M | $4.67M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $99.09M | $107.83M | $145.30M | $158.58M | $176.35M | $214.68M |
| Accounts payable | $861.00K | $1.16M | $996.00K | $1.16M | $3.69M | $1.51M |
| Total current liabilities | $11.45M | $11.05M | $14.89M | $13.43M | $13.55M | $14.82M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $12.43M | $12.32M | $16.70M | $15.55M | $15.96M | $17.79M |
| Retained earnings | -$311.89M | -$293.92M | -$255.90M | -$237.66M | -$216.66M | -$174.15M |
| Total equity | $86.67M | $95.52M | $128.60M | $143.04M | $160.39M | $196.89M |